Literature DB >> 526396

Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.

G L Sanders, P A Routledge, A Ward, D M Davies, M D Rawlins.   

Abstract

1 Mean steady-state plasma concentrations of labetalol (labetalol Css) in 17 hypertensive patients undergoing chronic treatment with this drug, have been examined in relation to dose, fall in BP, and beta-blockade. 2 A significant relationship (rs = 0.81, P less than 0.001) was observed between labetalol Css and daily dose. 3 No correlation was found between labetalol Css and antihypertensive response. 4 In thirteen patients, there seemed to be significant relationship between labetalol Css and beta-blockade (rs = 0.72, P less than 0.005). In three patients, the degree of beta-blockade was disproportionate to the drug concentration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526396      PMCID: PMC1429732     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

2.  Intravenously administered isoproterenol sulfate dose-response curves in man.

Authors:  C F George; M E Conolly; T Fenyvesi; R Briant; C T Dollery
Journal:  Arch Intern Med       Date:  1972-09

3.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

Review 4.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Labetalol, a cross-over double blind controlled trial.

Authors:  G L Sanders; P A Routledge; J G Rao; G M Gales; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

  6 in total
  3 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.